Advertisement

Topics

Britannia Pharmaceuticals Ltd Strategic SWOT Analysis Review [Updated: 08022017] Prices from USD $300

19:08 EST 26 Feb 2017 | BioPortfolio Reports

Britannia Pharmaceuticals Ltd Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This uptotheminute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

Business description A detailed description of the company's operations and business divisions.
Corporate strategy GlobalData's summarization of the company's business strategy.
SWOT analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list of key locations and subsidiaries of the company, including contact details.
Key manufacturing facilities A list of key manufacturing facilities of the company.

Highlights

Britannia Pharmaceuticals Ltd BPL is a UK based pharmaceutical company, which specializes in orphan drugs drugs for rare diseases affecting small patient populations. The company develops and markets products in the area of Parkinson's disease, wound healing and respiratory disorders. It is also focuses on evaluating opportunities for the neurology market and exploring ways to bring new products into the market. Its products include apomorphine hydrochlorode, a dopamine agonist. In addition, the company also developed nonopiate based therapeutics for the treatment of opiate detoxification and withdrawal. BPL is the subsidiary of the STADA Arzneimittel AG group of companies. BPL is headquartered in Berkshire, the UK.

Reasons to Buy

Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.
Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Original Article: Britannia Pharmaceuticals Ltd Strategic SWOT Analysis Review [Updated: 08022017] Prices from USD $300

NEXT ARTICLE

More From BioPortfolio on "Britannia Pharmaceuticals Ltd Strategic SWOT Analysis Review [Updated: 08022017] Prices from USD $300"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...